Syngenta plans Hong Kong listing worth up to $10 billion, sources say

Reuters
02/05
UPDATE 3-Syngenta plans Hong Kong listing worth up to $10 billion, sources say

Seeds and chemicals firm aims to float up to 20% stake in 2026

Banks are in early stages of talks

Proceeds earmarked for reducing debt, growth

IPO could be third biggest since 2021

Adds further details on how the IPO could affect the company, analyst comment

By John Revill, Oliver Hirt and Kane Wu

ZURICH/HONG KONG, Feb 5 (Reuters) - Syngenta Group is targeting a Hong Kong listing that could raise as much as $10 billion, two sources with knowledge of the plans said, setting the Swiss agrichemicals and seeds group on course for one of the world's biggest IPOs in recent years.

Syngenta, owned by Chinese state-owned Sinochem, is in talks with several banks to arrange the deal, the sources said, declining to be named as they were not authorised to speak to the media.

The company could float up to 20% of its shares, the sources said, adding that the size and timing of the offering was not final and could change depending on market conditions.

If it raised $10 billion, the flotation would be the third biggest globally in the last five years, after Rivian Automotive RIVN.O in 2021 and LG Energy Solution 373220.KS in 2022, according to Dealogic data.

"We do not comment on market rumours. We will continue to assess our capital markets strategies based on market conditions and other relevant factors that are in the best interests of our shareholders," Syngenta said, after Reuters was first to report the IPO plan earlier on Thursday.

"As we have always said, we intend to return to the capital markets when the time is right," Syngenta added.

The Basel-based company competes with U.S. Corteva group CTVA.N, as well as Germany's BASF BASFn.DE and Bayer BAYGn.DE, producing seeds and sprays that help farmers protect crops from weeds, insects and disease.

"The IPO environment has improved significantly over the past few quarters, and the agricultural sector is currently on the way up, but far off peaking, which makes this an attractive sector," said Markus Mayer, head of capital markets at Baader Bank.

Syngenta is in talks with banks including Goldman Sachs GS.N, UBS UBSG.S and Chinese investment bank CICC 601995.SS, as well as Morgan Stanley MS.N and HSBC HSBA.L, the sources said.

CICC, UBS and HSBC declined to comment, while Goldman Sachs and Morgan Stanley did not immediately respond to requests for comment.

The potential Hong Kong listing would come two years after Syngenta scrapped its application for an IPO on the Shanghai Stock Exchange, citing the industry environment and weakness in China's equity market.

HONG KONG FUNDRAISING MOMENTUM

No decision has been made on the IPO size, which could range from 10% to 20%, and raise $5 billion to $10 billion, one of the sources said.

No bank mandates have been agreed, the person added, with the process only just starting and Syngenta aiming to complete the IPO by the end of 2026.

Syngenta would use part of the IPO proceeds to reduce debt, the sources said. Net debt stood at $24.8 billion at the end of 2024, according to the company.

Proceeds could also be used to fund research and development and acquisitions. Syngenta typically spends about $2 billion per year on R&D and wants to expand its pipeline of new products.

Developing new seeds and insecticides can take up to 10 years and cost around $300 million, but newer products are more effective, used in smaller amounts, and offer higher margins.

The company also plans to expand its artificial intelligence tools, which include systems that give advice to smaller farmers.

The listing plan is partly driven by a desire to reduce Chinese ownership, two of the sources said, which could help ease U.S. concerns at a time of heightened trade tensions.

Arkansas ordered Syngenta to sell 160 acres (65 hectares) of farmland in 2023 because of its Chinese ownership, amid broader scrutiny of foreign land holdings.

The listing plan comes after Syngenta reported an improvement in its recent results, with profits rising 25% in the first nine months of 2025, despite slightly lower sales.

Syngenta was formed in 2000 from the merger of Novartis' and AstraZeneca's agribusinesses and was acquired by China National Chemical Corp, or ChemChina, for $43 billion in 2017 before being folded into Sinochem.

The planned flotation would add to renewed fundraising momentum in Hong Kong after the city reclaimed the top spot globally for IPO proceeds in 2025. Companies raised about $37.2 billion in Hong Kong main-board listings last year, LSEG data showed.

The Asian financial hub has got off to one of its strongest starts for years in 2026. In January, 12 companies listed, raising about $4.2 billion, according to LSEG data.

(Reporting by John Revill and Oliver Hirt in Zurich, Kane Wu in Hong Kong, and Yantoultra Ngui in Singapore. Editing by Sumeet Chatterjee, Elaine Hardcastle and Mark Potter)

((John.Revill@thomsonreuters.com; +41 41 528 36 37; Reuters Messaging: john.revill.thomsonreuters.com@reuters.net))

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10